Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib

Megumi Koshiishi1, Toru Odate2, Yukie Nakagawa1, Jun Suzuki1, Takuya Kumagai1, Ichiro Kawashima1, Takeo Yamamoto1, Kei Nakajima1, Masaru Tanaka1, Naoki Oishi2, Tetuso Kondo2 and Keita Kirito1

Abstract:
A 71-year-old woman with a four-year history of chronic lymphocytic leukemia (CLL) received ibrutinib as initial treatment due to progressive anemia and thrombocytopenia. Eleven months after the start of the treatments, although her cytopenia had ameliorated, she developed classic Hodgkin lymphoma, a rare form of Richter’s transformation. She was successfully treated with two courses of Adriamycin, Vinblastin, Bleomycin and dacarbazine followed by radiotherapy. In general, several clinical, genetic and molecular factors are associated with Richter’s transformation. In addition, our present case suggested that ibrutinib could be a potential risk factor for Richter’s transformation in CLL patients.

Key words: CLL, ibrutinib, Richter’s transformation

Introduction
The introduction of ibrutinib, a major Bruton tyrosine kinase inhibitor (BTKi), improves the prognosis of chronic lymphocytic leukemia (CLL), and ibrutinib is now widely used in clinical settings for both relapsed/refractory cases and initially diagnosed cases (1, 2). However, while ibrutinib does induce durable antitumor activity in CLL patients, a significant proportion of patients discontinue therapy due to progression of CLL or transformation to another type of aggressive lymphoproliferative malignancy, known as Richter’s transformation (RT) (3).

According to recent clinical studies, approximately 10% to 20% of patients develop RT upon treatment with ibrutinib (3-5). These studies also indicated that RT development during ibrutinib treatment led to unique clinical findings. First, the RT associated with ibrutinib develops earlier in the clinical course than conventional types [please define×], with most patients experiencing transformation within one year of the initiation of ibrutinib treatment, which differs from the progression of CLL. Second, relapsed/refractory patients with a history of chemotherapy, especially those treated with purine analog-containing regimens, tended to develop RT during ibrutinib treatment (2). Finally, transformation after ibrutinib treatment tended to lead to unique pathological findings. Several studies analyzing RT after ibrutinib treatment have shown a relatively high incidence of transformation to Hodgkin lymphoma (5, 4).

We herein report a case of CLL transformation to classic Hodgkin lymphoma upon treatment with ibrutinib. Although the patient received ibrutinib as initial chemotherapy, RT occurred within 12 months of the initiation of the ibrutinib regimen.

Case Report
A 71-year-old woman with a 4-year history of untreated CLL was referred to our institution due to progressive anemia and thrombocytopenia. At the time of her referral, the
patient’s complete blood cell counts were as follows: white blood cell count of 23.9×10^9/L, hemoglobin level of 9.2 g/dL and platelet count of 114×10^9/L. In contrast, the bone marrow samples show a normal variant pattern, as previously confirmed. The patient was treated with two courses of adriamycin, vinblastin, bleomycin and dacarbazine (ABVD) followed by involved-field radiotherapy, and she achieved complete remission of Hodgkin lymphoma. Despite ibrutinib being discontinued after the diagnosis of RT, hematological improvement has been maintained thus far.

Discussion

Historically, the incidence of RT has been reported to be 2%-10% among CLL patients (7). Common pathological findings of RT are diffuse large-B cell lymphoma (DLBCL), and less frequently, CLL patients show transformation to Hodgkin lymphoma. Studies performed before the introduction of novel agents, i.e. BTK inhibitors or venetoclax, found that the incidence of classic Hodgkin lymphoma transformation was less than 10% that of RT. A retrospective study of 4,121 CLL patients from MD Anderson Cancer Center indicated that only 18 patients (0.4%) developed Hodgkin-like transformation (8). A study from the Mayo Clinic reported that 26 of 3,387 CLL patients (0.7%) showed transformation to Hodgkin lymphoma (9).

Several clinical, genetic and molecular factors have been statistically proven to be associated with RT of CLL (7). An enlarged lymph node exceeding 3 cm in size was established as a risk factor for RT. Regarding chromosomal abnormalities, the presence of trisomy 12, del(17) or del(11q) was considered a risk factor for RT. The absence of del(13) is also a genetic change associated with RT. Molecular studies have identified the disruption of the TP53 gene, gain-of-function NOTCH1 mutation, or deletion of CDKN2A/B as risk factors for RT (7).

However, these previous findings were mainly drawn from observations based on total cases of RT largely composed of the DLBCL type. Therefore, little is known about the risk factors specifically associated with Hodgkin lymphoma transformation. Case series studies have suggested a possible role of immunosuppression by fludarabine and EBV infection in the transformation to Hodgkin lymphoma; however, others have found no meaningful association (10). Interestingly, recent retrospective studies and a line of case reports have suggested that the incidence of Hodgkin lymphoma transformation was relatively high after BTKi treatment compared to historical data. The Polish adult leukemia group reported that all three patients who developed RT during ibrutinib treatment had a Hodgkin lymphoma phenotype (4, 11). Ahn et al. reported 5 transformation cases in a phase 2 trial with ibrutinib for CLL (5). Among these five cases, two were confirmed to have Hodgkin lymphoma (5). Furthermore, six more CLL cases, including the case presented herein, with Hodgkin lymphoma transformation after BTKi treatment have been reported (12-15). However, most of these cases were relapsed and/or refractory to several pre-
vious lines of chemotherapy, including purine analogs. Therefore, the RT that develops upon BTKi treatment may not be the result of the use of these agents but instead associated with the pretreatment status of the disease (7). Indeed, Taneja et al. reported that two CLL patients with pre-existing Reed-Sternberg cells in the lymph nodes before the initiation of BTKi treatment transformed to Hodgkin lymphoma (15). This notion is supported by the finding that RT was not observed in a phase 3 study of ibrutinib for chemotherapy-naive CLL patients (2).

The present findings provide some important information to bear in mind when considering the potential risk of ibrutinib for inducing RT. Our patient did not have a history of chemotherapy and received ibrutinib as a first-line treatment. From a genetics perspective, the patient did not have trisomy of 12 or del(17), both of which are well accepted genetic risk factors for RT (7). In addition, a pathological analysis revealed no contribution from EBV to the transformation of this patient. A chromosomal analysis showed that the transformed cells acquired complex karyotype abnormalities, but the CLL cells did not. These findings suggest that the administration of ibrutinib might have induced genetic instability and progression to transformation in this patient. Importantly, Compagno et al. found that ibrutinib enhanced the expression of activation-induced cytidine deaminase (AID) in CLL cells (16). Since the overexpression of AID induces mutagenic activity, these authors raised concerns about a potential mutagenic risk to patients receiving long-term therapy with ibrutinib (16). Furthermore, a recent observational study indicated the association of a secondary cancer risk with the use of ibrutinib in CLL patients (17).

It is important to consider the potential risk of ibrutinib for inducing transformation and carefully observe the emergence of other types of B-cell neoplasms in CLL patients treated with ibrutinib.

The authors state that they have no Conflict of Interest (COI).

References
1. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine 369: 32-42, 2013.
2. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine 373: 2425-2437, 2015.
3. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncology 1: 80-87, 2015.
4. Iskierka-Jaźdżewska E, Pula B, Szeremet A, et al. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A re-
port from the Polish Adult Leukemia Study Group (PALG). Advances in Clinical and Experimental Medicine 28: 1051-1057, 2019.
5. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129: 1469-1479, 2017.
6. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131: 2745-2760, 2018.
7. Khan M, Siddiqi R, Thompson PA. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. Annals of Hematology 97: 1-15, 2018.
8. Tsimeridou AM, O’Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: The M. D. Anderson Cancer Center experience. Cancer 107: 1294-1302, 2006.
9. Parikh SA, Habermann TM, Chaffee KG, et al. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. American Journal of Hematology 90: 334-338, 2015.
10. Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: A retrospective analysis of world literature. British Journal of Haematology 156: 50-66, 2012.
11. Jamroziak K, Szymczyk A, Hus M, et al. Hodgkin’s variant of Richter’s transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG). European Journal of Haematology 100: 389-391, 2018.
12. Quesada AE, Konoplev S. Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome). Blood 130: 2151, 2017.
13. Glavey S, Quinn J, McCloy M, et al. Emergence of Bruton’s tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia. European Journal of Haematology 99: 378-380, 2017.
14. Sachanas S, Pangalis GA, Moschogiannis M, et al. Hodgkin lymphoma transformation of chronic lymphocytic leukemia under ibrutinib therapy: Chance association or therapy-related? Anticancer Research 37: 3277-3280, 2017.
15. Taneja A, Jones J, Pittaluga S, et al. Richter transformation to Hodgkin lymphoma on Bruton’s tyrosine kinase inhibitor therapy. Leuk Lymphoma 60: 519-522, 2019.
16. Compagno M, Wang Q, Pighi C, et al. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. Nature 542: 483-493, 2017.
17. Bond DA, Huang Y, Fisher JL, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia 34: 3197-3205, 2020.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).